A groundbreaking new medication called Zuranalone, commonly known as Zurzuvae, is poised to revolutionize the treatment of postpartum depression.
Expected to be available in the coming months, it will be the first FDA-approved oral medication specifically designed for this purpose. The medication has the potential to improve symptoms within just three days, a significant advancement over existing treatments that could take weeks to show effects.
The new medication comes as Senator Samra Brouk, Chair of the Senate Mental Health Committee, emphasizes the need to destigmatize maternal mental health conditions, which are the most common pregnancy health complications.
The short-term treatment lasts 14 days but can have effects lasting up to 45 days, allowing for a longer-term treatment plan to be developed. While the cost of the medication is still unknown, tests are promising in determining its compatibility with breastfeeding. For those struggling with postpartum depression, experts urge immediate consultation with a physician and note that the National Suicide Prevention hotline is available by dialing 988.
FingerLakes1.com is the region’s leading all-digital news publication. The company was founded in 1998 and has been keeping residents informed for more than two decades. Have a lead? Send it to [email protected].